• Orthocell increases equity stake in Marine Biomedical to 12% for AU$1M
• Secures first right of refusal for global distribution rights to Marine Biomedical's PearlBone™ bone substitute
• PearlBone is an innovative, next-generation biomaterial for bone repair and regeneration

Orthocell Limited (ASX: OCC) has executed a Memorandum of Understanding (MoU) with Marine Biomedical Pty Ltd, a Western Australian biotechnology company, to increase its existing equity stake from 1.72% to 11.70% for a total investment of AU$1.05 million. The investment is contingent on Orthocell securing first right of refusal in relation to the global distribution rights to Marine Biomedical's products, including PearlBone™ - a novel, next-generation bone substitute product developed using sustainably sourced pearl shells from Western Australia's Kimberley coast. This strategic agreement strengthens Orthocell's biologic product portfolio by adding a next-generation bone substitute alongside its existing nerve and tendon repair technologies. It also enables Orthocell to leverage its established distribution networks, particularly in the United States, where the company maintains deep relationships with specialist distributors and leading orthopaedic and plastic surgeons. Marine Biomedical is nearing completion of a pivotal study designed to support a U.S. FDA 510(k) marketing submission in Q1 CY2026, which will enable commercial distribution of the PearlBone in the US$1.6 billion bone graft and substitute market.

Marine Biomedical is nearing completion of a pivotal study designed to support a U.S. FDA 510(k) marketing submission in Q1 CY2026 for the PearlBone product, which will enable commercial distribution in the US$1.6 billion bone graft and substitute market.

Orthocell is well positioned to leverage its established distribution networks, particularly in the United States, to bring the PearlBone product to market and capitalize on the US$1.6 billion bone graft and substitute market opportunity.